THE global gingivitis treatment marketvalued at 7 billion US dollars in 2023, is projected to grow at a steady CAGR 4.8% over the next decade, reaching approx 11.19 billion US dollars to 2033. This growth is attributed to the increasing prevalence of gum disease, increased awareness about oral health, and the continuous introduction of innovative products and treatment technologies. From 2018 to 2022, the market exhibited a CAGR of 3.2%, reflecting the steady demand for effective treatments for gingivitis.
Gingivitis, an inflammation of the gum tissue surrounding the teeth, is a common condition that can lead to more serious oral health problems if left untreated. The gingivitis treatment market includes a wide range of products and services, ranging from therapeutic mouthwashes and toothpastes to advanced dental care procedures, all aimed at reducing inflammation and promoting gum health.
With increasing investment in research and the development of more effective treatment solutions, the market is set to offer improved options for managing gingivitis, improving oral health and preventing progression to more serious gum disease on a global scale.
What are the challenges faced in Gingivitis Treatment Market?
Expensive cost of treatment to restrain market growth
Despite the growing awareness of the importance of maintaining good oral health, many people are still unaware of gum disease and its treatment options. This can limit the demand for gingivitis treatment products and services.
Additionally, the cost of gingivitis treatment can be a barrier for many people, especially those without insurance coverage. This can limit demand for treatment options and make it harder for companies to generate revenue.
Companies operating in the gingivitis treatment market must comply with regulatory requirements related to product safety and efficacy. This can be difficult and expensive, particularly for smaller companies without significant resources. Overall, companies operating in the gingivitis treatment market need to address these challenges to capture market share and drive growth. By developing innovative products, building strong brands and effectively communicating the benefits of their offerings, companies can overcome these challenges and succeed in this market.
Market Competition
Key players in the market include companies such as Fibrocell Sciences, Tolmar Inc., Eli Lilly & Company, Align Technology, Dentsply International, 3M Company, Ultradent Products Inc., Nobel Biocare Holdings AG, Glidewell Laboratories, Orapharma, Kaken Pharmaceutical and Valeant Pharmaceuticals Int., along with healthcare providers and technology companies among other global players.
- In October 2022, it was announced that a rapid test for gum disease was being developed by researchers at the University of Birmingham. The detector, designed for use in point-of-care environments such as dental surgeries or pharmacies, is expected to help in the early detection of heart or lung disease, type 2 diabetes and rheumatoid arthritis. A new technique developed by Professor Tim Albrecht from the School of Chemistry and Dr Melissa Grant from the University’s School of Dentistry provides a quick and accurate assessment of gum disease using a saliva sample, which can be collected in any healthcare setting .
The technique involves a specialized probe and detector that provide quantitative measurements of biomarkers that indicate the presence and severity of gum disease. These biomarkers were validated and recognized by the university’s Periodontal Research Group and published in the Journal of Clinical Periodontology earlier this year. The researchers have secured funding from the EPSRC Impact Acceleration Account to create a prototype of the device, which is expected to be on the market within a year.
Profiles of key companies
Fibrocell Sciences, Tolmar Inc., Eli Lilly & Company, Align Technology, Dentsply International, 3M Company, Ultradent Products Inc., Nobel Biocare Holdings AG, Glidewell Laboratories, Orapharma, Kaken Pharmaceutical and Valeant Pharmaceuticals Int.
Key Segments Recorded in Gingivitis Treatment Industry Research
Drug class:
- Veetids
- Erythrokin
- Minocycline
- Doxycycline
- Clindamycin
- Chlorhexidine
- Acetaminophen
- Ibuprofen
- Lidocaine
Route of administration:
End user:
- Hospital Pharmacy
- Retail Pharmacy
- Online pharmacy
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) has over 12 years of experience in the Healthcare, Medical Device and Pharmaceutical industries. His curious and analytical nature helped shape his career as a researcher.
Identifying key challenges facing clients and devising powerful case-based solutions to empower them with strategic decision-making capabilities comes naturally to him. His main expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and been cited in journals including The Journal of mHealth, ITN Online and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award recipient, and member of the Greater New York Chamber of Commerce) offers deep insights into the drivers that fuel market demand. FMI is the leading global provider of market intelligence, consulting, advisory services and events for the packaging, food and beverage, consumer technology, healthcare, industrial and chemical markets. With a massive team of over 400 analysts worldwide, FMI provides global, regional and local expertise on various sectors and industry trends in over 110 countries.
Contact us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Inquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
